Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 2/20 | 0.63 |
| ▸ | DRD4 | P21917 | 9/20 | 0.60 |
| ▸ | DRD2 | P14416 | 8/20 | 0.60 |
| ▸ | DRD3 | P35462 | 6/20 | 0.60 |
| ▸ | HTR1D | P28221 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7751165 | 0.94 | KDM4E (0.66) | HTR1BDRD4DRD2DRD3HTR1D | |
| SCHEMBL14176538 | 0.87 | KDM4E (0.56) | HTR1BDRD4DRD2DRD3HTR1D | |
| SCHEMBL14176537 | 0.82 | GAA (0.50) | HTR1BDRD4DRD2KDM4EALDH1A1 | |
| SCHEMBL23664610 | 0.81 | KDM4E (0.60) | DRD4DRD2DRD3KDM4EALDH1A1 | |
| SCHEMBL8066260 | 0.81 | DRD4 (0.60) | HTR1BDRD4DRD2DRD3HTR1D | |
| SCHEMBL9029311 | 0.79 | KCNA3 (0.53) | HTR1BDRD4DRD2DRD3HTR1D | |
| SCHEMBL22144524 | 0.78 | DRD4 (0.74) | HTR1BDRD4DRD2DRD3HTR1D | |
| SCHEMBL8366754 | 0.78 | HTR1B (0.56) | HTR1BDRD4DRD2DRD3HTR1D | |
| SCHEMBL8099108 | 0.78 | HTR1B (0.56) | HTR1BDRD4DRD2DRD3HTR1D | |
| SCHEMBL1109801 | 0.78 | HTR1B (1.00) | HTR1BDRD4DRD2DRD3HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | HTR1B 1660/4885DRD4 910/4885DRD2 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.